Mereo BioPharma Group (Mereo BioPharma Group) EPS (Basic) : $-0.20 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group EPS (Basic)?

Mereo BioPharma Group's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was $-0.07. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.20.

Mereo BioPharma Group's EPS (Diluted) for the six months ended in Dec. 2023 was $-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.20.

Mereo BioPharma Group's EPS without NRI for the six months ended in Dec. 2023 was $-0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.19.

During the past 3 years, the average EPS without NRI Growth Rate was 39.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 42.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Mereo BioPharma Group's highest 3-Year average EPS without NRI Growth Rate was 45.30% per year. The lowest was 4.60% per year. And the median was 35.60% per year.

Mereo BioPharma Group EPS (Basic) Historical Data

The historical data trend for Mereo BioPharma Group's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group EPS (Basic) Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-2.56

-3.27

0.14

-0.35

-0.20

Mereo BioPharma Group Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial												-	-0.18	-0.17	-0.13	-0.07

Mereo BioPharma Group EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Mereo BioPharma Group's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-29.466	-	0)	/	131.891
	=	-0.22

Mereo BioPharma Group's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-15.554	-	0)	/	138.364
	=	-0.11

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.20

Mereo BioPharma Group (NAS:MREO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Mereo BioPharma Group EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.